Boston Scientific’s Ranger DCB and Medtronic’s In.Pact Admiral DCB – Head to Head

Share this story

This first of it’s kind trial compares two leading DCB technologies.

Boston Scientific’s drug-coated balloon goes up against Medtronic’s DCB in first-of-its-kind trial

Top-line results from a head-to-head trial comparing Boston Scientific‘s (NYSE:BSX) Ranger drug-coated balloon and Medtronic‘s (NYSE:MDT) In.Pact Admiral DCB found no statistically significant difference in patency rates between the two drug-device products.

The trial is the first of its kind, according to Boston Scientific’s president of peripheral interventions, Jeff Mirviss.

“As a leader in the peripheral space, we wanted to deliver the type of evidence that could help physicians and hospital systems utilize more evidence-based medicine in the field. We wanted to do the type of trial that could advance the field forward,” Mirviss told Drug Delivery Business News.

Read full story at Drug Delivery Business News

Leave a Comment

Your email address will not be published. Required fields are marked *

*